Intriguingly, both NAT-BRET and NEO-BRET biosensors showed in-creased BRET signal in primary cancer cells derived from platinum-resistant relapse patients but not from treatment-naive or platinum-sensitive relapse patients. The gene discussed is BRD2; the disease is cancer.